

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
22 August 2024 (22.08.2024)



(10) International Publication Number
WO 2024/173762 A3

(51) International Patent Classification:

A61K 31/712 (2006.01) C12N 15/113 (2010.01)
A61K 31/7125 (2006.01) A61P 25/16 (2006.01)
C07H 21/04 (2006.01)

SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(21) International Application Number:

PCT/US2024/016102

(22) International Filing Date:

16 February 2024 (16.02.2024)

(88) Date of publication of the international search report:

17 October 2024 (17.10.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/485,807 17 February 2023 (17.02.2023) US

(71) Applicant: IONIS PHARMACEUTICALS, INC.

[US/US]; 2855 Gazelle Court, Carlsbad, CA 92010 (US).

(72) Inventors: ZHAO, Hien, Thuy; c/o Ionis Pharmaceuticals,

Inc., 2855 Gazelle Ct., Carlsbad, CA 92010 (US). SETH,
Punit, P.; 6773 Mallee St., Carlsbad, CA 92011 (US).

(74) Agent: SCARR, Rebecca, B. et al.; McNeill Baur PLLC,

125 Cambridge Park Dr, Suite 301, Cambridge, MA 02140
(US).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,

(54) Title: COMPOUNDS AND METHODS FOR REDUCING APP EXPRESSION

(57) Abstract: Provided are compounds, methods, and pharmaceutical compositions for reducing the amount or activity of APP RNA in a cell or a subject, and in certain instances reducing the amount of APP protein in a cell or a subject. Such compounds, methods, and pharmaceutical compositions are useful to ameliorate at least one symptom or hallmark of a neurodegenerative disease or disorder associated with APP. Such symptoms and hallmarks include cognitive impairment, including a decline in memory and language skills, behavioral and psychological symptoms such as apathy and lack of motivation, gait disturbances, seizures, progressive dementia, and abnormal amyloid deposits.



WO 2024/173762 A3